The Service Tree lists all services in "branched" groups, starting with the very general and moving to the very specific. Click on the name of any group name to see the sub-groups available within it. Click on a service code to see its details and the providers who offer that service.
Naltrexone Based MAT Programs
Taxonomy Code: RX-8450.5000-600
Medication assisted treatment (MAT) programs that use Naltrexone (Vivitrol) to help people with an opioid or alcohol use disorder abstain from or reduce their use of opioids or alcohol. The medication comes in a pill form or as an injectable. The pill form of naltrexone (ReVia, Depade) can be taken daily. The injectable extended-release form of the drug (Vivitrol) is administered intramuscular once a month. Naltrexone can be prescribed by any health care provider who is licensed to prescribe medications. To reduce the risk of precipitated withdrawal, patients are warned to abstain from illegal opioids and opioid medication for a minimum of 7-10 days before starting Naltrexone. If switching from methadone to naltrexone, the patient has to be completely withdrawn from the opioids. Naltrexone blocks the euphoric and sedative effects of drugs such as heroin, morphine, and codeine. It works differently in the body than buprenophine and methadone, which activate opioid receptors in the body that suppress cravings. Naltrexone binds and blocks opioid receptors, and is reported to reduce opioid cravings. There is no abuse or diversion potential with naltrexone. Naltrexone can also be used to treat alcohol use disorders. Oral Naltrexone and extended-release injectable Naltrexone can be used for the treatment of alcohol dependence in patients who can abstain from alcohol in an outpatient setting before the initiation of treatment. Naltrexone has not been shown to be effective in patients who are drinking at treatment initiation. Both formulations may have the greatest benefit in patients who can discontinue drinking on their own for several days before treatment initiation.